Dr Cheri Deal discusses the use of growth hormone in children with Prader-Willi syndrome, the importance of multidisciplinary care and the future of treatment for this genetic condition.
Being overweight or obese in early childhood is associated with having increased cardiometabolic risk in preteens, researchers report.
A meta-analysis confirms growth and body composition benefits for children with Prader–Willi syndrome given recombinant human growth hormone.
Adding liraglutide 3.0 mg to lifestyle therapy increases weight loss in obese adolescents, show the findings of a placebo-controlled phase 3 trial.
An oral glucose tolerance test may identify youths with a more adverse cardiometabolic profile than a fasting plasma glucose test does, say researchers.
Factors including age at diagnosis and the specific disease influence the likelihood of children with chronic endocrine conditions being lost to follow-up, show French study findings.
The prevalence of overweight and obesity remains high among European children, say researchers, with “worrisome” rising trends in some countries, despite stabilising rates and downwards trends in other countries.
In this podcast, Dr Shylaja Srinivasan discusses the care of children and adolescents with type 2 diabetes, and how the findings of the TODAY2 and Ellipse trials will inform treatment decisions.
The latest TODAY2 findings show rapid accumulation of cardiovascular risk factors and diabetes complications following a diagnosis of type 2 diabetes during childhood or adolescence.
The randomised Ellipse trial has demonstrated significant blood glucose reductions with the glucagon-like peptide-1 receptor agonist liraglutide in children and adolescents with type 2 diabetes already taking metformin.